In this issue:
PSMA and FDG-PET as biomarkers for 177Lu-PSMA outcomes
Continuous enzalutamide after progression of mCRPC
Prognostic significance of pathogenic gene variants in hormonal therapy
Metastasis-directed therapy for molecularly-defined oligometastatic prostate cancer
Oligometastatic HSPC treated with ADT and EBRT
Salvage radical prostatectomy after initial irreversible electroporation
Triplet therapy for metastatic HSPC
Local failure after radiotherapy
18F-PSMA-11 vs 68Ga-PSMA-11 PET/CT
Orgasmic dysfunction after RARP
Please login below to download this issue (PDF)